<p>Soleno Therapeutics, Inc.（納斯達克代碼：SLNO - 獲取免費報告）的股票在週三的午盤交易中下跌了 3.4%。該公司的股價最低曾達到 48.50 美元，最後交易價為 48.40 美元。在午盤交易中，約有 379,566 股成交，較平均每日成交量 525,409 股下降了 28%。該股票此前收盤價為 50.11 美元。</p>
<p>獲取 <strong>Soleno Therapeutics</strong> 的提醒：</p>
<h2>分析師評級變動</h2>
<p>SLNO 曾受到多份分析師報告的關注。Lifesci Capital 在 2 月 4 日的研究報告中將 Soleno Therapeutics 的評級上調至 “強力買入”。Stifel Nicolaus 在 3 月 5 日的研究報告中開始覆蓋 Soleno Therapeutics，給予 “買入” 評級和 74.00 美元的目標價。HC Wainwright 在 3 月 3 日的研究報告中重申了 “買入” 評級，並給予 Soleno Therapeutics 70.00 美元的目標價。最後，Robert W. Baird 在 12 月 2 日的報告中重申了 “跑贏大盤” 評級，並給予 Soleno Therapeutics 72.00 美元的目標價。五位分析師對該股票給予了買入評級，兩位分析師給予了強力買入評級。根據 MarketBeat.com 的數據，該股票目前的共識評級為 “買入”，平均目標價為 71.20 美元。</p>
<p><strong>獲取我們對 Soleno Therapeutics 的最新分析</strong></p>
<h2>Soleno Therapeutics 價格表現</h2>
<p>該股票的市值為 22.2 億美元，市盈率為-14.55，貝塔值為-1.70。該公司的 50 日移動平均線為 47.43 美元，200 日移動平均線為 49.77 美元。</p>
<p>Soleno Therapeutics（納斯達克代碼：SLNO - 獲取免費報告）最近在 3 月 5 日發佈了季度財報。該公司報告的每股收益為（1.27 美元），低於分析師的共識預期（0.86 美元）0.41 美元。平均而言，股票研究分析師預計 Soleno Therapeutics, Inc.在本年度的每股收益將為-3.72 美元。</p>
<h2>內部人士下注</h2>
<p>在其他消息中，內部人士 Kristen Yen 在 1 月 3 日的交易中出售了 2,340 股公司的股票。該股票以平均價格 46.18 美元出售，總交易額為 108,061.20 美元。出售後，內部人士現在持有 76,605 股公司的股票，價值約為 3,537,618.90 美元。這代表其持股比例減少了 2.96%。該交易已在證券交易委員會的法律文件中披露，相關信息可通過 SEC 網站訪問。此外，首席執行官 Bhatnagar Anish 在 1 月 2 日的交易中出售了 10,937 股公司的股票。該股票以平均價格 45.41 美元出售，總價值為 496,649.17 美元。出售後，首席執行官現在直接持有 708,616 股公司股票，價值 32,178,252.56 美元。這代表其持股比例減少了 1.52%。該交易的披露信息可在此處找到。內部人士在過去 90 天內出售了價值 790,119 美元的 17,360 股公司股票。公司內部人士持有 12.30% 的公司股票。</p>
<h2>Soleno Therapeutics 的機構交易</h2>
<p>一些大型投資者最近調整了對 SLNO 的持股。Victory Capital Management Inc.在第三季度將其在 Soleno Therapeutics 的持股增加了 25.9%。Victory Capital Management Inc.現在持有 13,509 股公司股票，價值 682,000 美元，此前在該期間內增持了 2,782 股。Intech Investment Management LLC 在第三季度購買了 Soleno Therapeutics 的新頭寸，價值 262,000 美元。HealthInvest Partners AB 在第三季度購買了 Soleno Therapeutics 的新頭寸，價值 1,332,000 美元。Charles Schwab Investment Management Inc.在第三季度將其在 Soleno Therapeutics 的持股增加了 208.1%。Charles Schwab Investment Management Inc.現在持有 192,597 股公司股票，價值 9,724,000 美元，此前在上個季度增持了 130,080 股。最後，Westfield Capital Management Co. LP 在第三季度購買了 Soleno Therapeutics 的新頭寸，價值 25,028,000 美元。對沖基金和其他機構投資者持有公司 97.42% 的股票。</p>
<h2>關於 Soleno Therapeutics</h2>
<p>（獲取免費報告）</p>
<p>Soleno Therapeutics, Inc.是一家臨牀階段的生物製藥公司，專注於開發和商業化用於治療罕見疾病的新型療法。其主要候選藥物是氟氯噻噸緩釋片，這是一種每日一次的口服藥物，目前正在進行治療普拉德 - 威利綜合症的第三階段臨牀試驗。</p>
<h2>特色故事</h2>
<ul>
<li>五隻我們更看好的股票，勝過 Soleno Therapeutics</li>
<li>賣空 - 利與弊</li>
<li>GTC 2025 對 NVIDIA 股票下一次重大走勢的信號</li>
<li>如何計算期權利潤</li>
<li>Alphabet 正式進入熊市——該買入了嗎？</li>
<li>期權交易 - 理解行使價格</li>
<li>D-Wave 與量子霸權：對投資者的影響</li>
</ul>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送電子郵件至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Soleno Therapeutics 嗎？</h2>
<p>在考慮 Soleno Therapeutics 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Soleno Therapeutics 並不在名單上。</p>
<p>雖然 Soleno Therapeutics 目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

Soleno治療

<p>Soleno Therapeutics（納斯達克代碼：SLNO）股價在午盤交易中下跌 3.4%，至 48.40 美元，交易量較平均水平下降 28%。分析師的評級意見不一，Lifesci Capital 將其評級上調至 “強力買入”，其他分析師則將目標價設定在 70.00 美元至 74.00 美元之間。該公司報告的季度每股收益為（1.27 美元），未能達到預期。內部交易顯示高管近期有出售股票的行為，而機構投資者持有 97.42% 的股份。Soleno 專注於開發罕見疾病的治療方案，其主要候選藥物正在進行普拉德 - 威利綜合症的第三階段臨牀試驗</p>

<p>Shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO - Get Free Report) dropped 3.4% during mid-day trading on Wednesday . The company traded as low as $48.50 and last traded at $48.40. Approximately 379,566 shares changed hands during mid-day trading, a decline of 28% from the average daily volume of 525,409 shares. The stock had previously closed at $50.11.</p>
<div class="lb-trans"><p>Soleno Therapeutics, Inc.（納斯達克代碼：SLNO - 獲取免費報告）的股票在週三的午盤交易中下跌了 3.4%。該公司的股價最低曾達到 48.50 美元，最後交易價為 48.40 美元。在午盤交易中，約有 379,566 股成交，較平均每日成交量 525,409 股下降了 28%。該股票此前收盤價為 50.11 美元。</p>
</div><p>Get <strong>Soleno Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Soleno Therapeutics</strong> 的提醒：</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析師評級變動</h2>
</div><p>SLNO has been the subject of a number of analyst reports. Lifesci Capital upgraded Soleno Therapeutics to a &#34;strong-buy&#34; rating in a research report on Tuesday, February 4th. Stifel Nicolaus initiated coverage on Soleno Therapeutics in a research report on Wednesday, March 5th. They issued a &#34;buy&#34; rating and a $74.00 price target for the company. HC Wainwright restated a &#34;buy&#34; rating and issued a $70.00 price target on shares of Soleno Therapeutics in a research report on Monday, March 3rd. Finally, Robert W. Baird reiterated an &#34;outperform&#34; rating and issued a $72.00 price objective on shares of Soleno Therapeutics in a report on Monday, December 2nd. Five analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of &#34;Buy&#34; and an average target price of $71.20.</p>
<div class="lb-trans"><p>SLNO 曾受到多份分析師報告的關注。Lifesci Capital 在 2 月 4 日的研究報告中將 Soleno Therapeutics 的評級上調至 “強力買入”。Stifel Nicolaus 在 3 月 5 日的研究報告中開始覆蓋 Soleno Therapeutics，給予 “買入” 評級和 74.00 美元的目標價。HC Wainwright 在 3 月 3 日的研究報告中重申了 “買入” 評級，並給予 Soleno Therapeutics 70.00 美元的目標價。最後，Robert W. Baird 在 12 月 2 日的報告中重申了 “跑贏大盤” 評級，並給予 Soleno Therapeutics 72.00 美元的目標價。五位分析師對該股票給予了買入評級，兩位分析師給予了強力買入評級。根據 MarketBeat.com 的數據，該股票目前的共識評級為 “買入”，平均目標價為 71.20 美元。</p>
</div><p><strong>Get Our Latest Analysis on Soleno Therapeutics</strong></p>
<div class="lb-trans"><p><strong>獲取我們對 Soleno Therapeutics 的最新分析</strong></p>
</div><h2>Soleno Therapeutics Price Performance</h2>
<div class="lb-trans"><h2>Soleno Therapeutics 價格表現</h2>
</div><p>The stock has a market capitalization of $2.22 billion, a price-to-earnings ratio of -14.55 and a beta of -1.70. The business has a fifty day moving average of $47.43 and a 200 day moving average of $49.77.</p>
<div class="lb-trans"><p>該股票的市值為 22.2 億美元，市盈率為-14.55，貝塔值為-1.70。該公司的 50 日移動平均線為 47.43 美元，200 日移動平均線為 49.77 美元。</p>
</div><p>Soleno Therapeutics (NASDAQ:SLNO - Get Free Report) last released its quarterly earnings results on Wednesday, March 5th. The company reported ($1.27) EPS for the quarter, missing analysts' consensus estimates of ($0.86) by ($0.41). On average, equities research analysts expect that Soleno Therapeutics, Inc. will post -3.72 EPS for the current year.</p>
<div class="lb-trans"><p>Soleno Therapeutics（納斯達克代碼：SLNO - 獲取免費報告）最近在 3 月 5 日發佈了季度財報。該公司報告的每股收益為（1.27 美元），低於分析師的共識預期（0.86 美元）0.41 美元。平均而言，股票研究分析師預計 Soleno Therapeutics, Inc.在本年度的每股收益將為-3.72 美元。</p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>內部人士下注</h2>
</div><p>In other news, insider Kristen Yen sold 2,340 shares of the company's stock in a transaction on Friday, January 3rd. The stock was sold at an average price of $46.18, for a total transaction of $108,061.20. Following the sale, the insider now owns 76,605 shares of the company's stock, valued at approximately $3,537,618.90. This represents a 2.96 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities &amp; Exchange Commission, which can be accessed through the SEC website. Also, CEO Bhatnagar Anish sold 10,937 shares of the company's stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $45.41, for a total value of $496,649.17. Following the sale, the chief executive officer now directly owns 708,616 shares in the company, valued at $32,178,252.56. This represents a 1.52 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 17,360 shares of company stock worth $790,119 over the last ninety days. Corporate insiders own 12.30% of the company's stock.</p>
<div class="lb-trans"><p>在其他消息中，內部人士 Kristen Yen 在 1 月 3 日的交易中出售了 2,340 股公司的股票。該股票以平均價格 46.18 美元出售，總交易額為 108,061.20 美元。出售後，內部人士現在持有 76,605 股公司的股票，價值約為 3,537,618.90 美元。這代表其持股比例減少了 2.96%。該交易已在證券交易委員會的法律文件中披露，相關信息可通過 SEC 網站訪問。此外，首席執行官 Bhatnagar Anish 在 1 月 2 日的交易中出售了 10,937 股公司的股票。該股票以平均價格 45.41 美元出售，總價值為 496,649.17 美元。出售後，首席執行官現在直接持有 708,616 股公司股票，價值 32,178,252.56 美元。這代表其持股比例減少了 1.52%。該交易的披露信息可在此處找到。內部人士在過去 90 天內出售了價值 790,119 美元的 17,360 股公司股票。公司內部人士持有 12.30% 的公司股票。</p>
</div><h2>Institutional Trading of Soleno Therapeutics</h2>
<div class="lb-trans"><h2>Soleno Therapeutics 的機構交易</h2>
</div><p>A number of large investors have recently modified their holdings of SLNO. Victory Capital Management Inc. increased its position in shares of Soleno Therapeutics by 25.9% during the third quarter. Victory Capital Management Inc. now owns 13,509 shares of the company's stock worth $682,000 after acquiring an additional 2,782 shares during the period. Intech Investment Management LLC purchased a new position in Soleno Therapeutics in the third quarter valued at $262,000. HealthInvest Partners AB purchased a new position in Soleno Therapeutics in the third quarter valued at $1,332,000. Charles Schwab Investment Management Inc. increased its holdings in Soleno Therapeutics by 208.1% in the third quarter. Charles Schwab Investment Management Inc. now owns 192,597 shares of the company's stock valued at $9,724,000 after buying an additional 130,080 shares during the last quarter. Finally, Westfield Capital Management Co. LP purchased a new position in Soleno Therapeutics in the third quarter valued at $25,028,000. Hedge funds and other institutional investors own 97.42% of the company's stock.</p>
<div class="lb-trans"><p>一些大型投資者最近調整了對 SLNO 的持股。Victory Capital Management Inc.在第三季度將其在 Soleno Therapeutics 的持股增加了 25.9%。Victory Capital Management Inc.現在持有 13,509 股公司股票，價值 682,000 美元，此前在該期間內增持了 2,782 股。Intech Investment Management LLC 在第三季度購買了 Soleno Therapeutics 的新頭寸，價值 262,000 美元。HealthInvest Partners AB 在第三季度購買了 Soleno Therapeutics 的新頭寸，價值 1,332,000 美元。Charles Schwab Investment Management Inc.在第三季度將其在 Soleno Therapeutics 的持股增加了 208.1%。Charles Schwab Investment Management Inc.現在持有 192,597 股公司股票，價值 9,724,000 美元，此前在上個季度增持了 130,080 股。最後，Westfield Capital Management Co. LP 在第三季度購買了 Soleno Therapeutics 的新頭寸，價值 25,028,000 美元。對沖基金和其他機構投資者持有公司 97.42% 的股票。</p>
</div><h2>About Soleno Therapeutics</h2>
<div class="lb-trans"><h2>關於 Soleno Therapeutics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.</p>
<div class="lb-trans"><p>Soleno Therapeutics, Inc.是一家臨牀階段的生物製藥公司，專注於開發和商業化用於治療罕見疾病的新型療法。其主要候選藥物是氟氯噻噸緩釋片，這是一種每日一次的口服藥物，目前正在進行治療普拉德 - 威利綜合症的第三階段臨牀試驗。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>特色故事</h2>
</div><ul>
<li>Five stocks we like better than Soleno Therapeutics</li>
<li>Short Selling - The Pros and Cons</li>
<li>What GTC 2025 Signals for NVIDIA Stock’s Next Big Move</li>
<li>How to Calculate Options Profits</li>
<li>Alphabet’s Officially In A Bear Market—Time To Buy?</li>
<li>Options Trading - Understanding Strike Price</li>
<li>D-Wave and Quantum Supremacy: Implications For Investors</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 Soleno Therapeutics</li>
<li>賣空 - 利與弊</li>
<li>GTC 2025 對 NVIDIA 股票下一次重大走勢的信號</li>
<li>如何計算期權利潤</li>
<li>Alphabet 正式進入熊市——該買入了嗎？</li>
<li>期權交易 - 理解行使價格</li>
<li>D-Wave 與量子霸權：對投資者的影響</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送電子郵件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Soleno Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Soleno Therapeutics 嗎？</h2>
</div><p>Before you consider Soleno Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Soleno Therapeutics 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Soleno Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Soleno Therapeutics 並不在名單上。</p>
</div><p>While Soleno Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Soleno Therapeutics 目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Soleno 治療 (NASDAQ:SLNO) 股價下跌 3.4% - 你應該賣出嗎？